SecBot SecBot
8-K ·Filed Nov 3, 2026

RVTY

REVVITY, INC.
BULLISH
Impact 6/10
Horizonweeks Processed13d 15h ago SEC0000031791-26-000031
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

The raised full-year guidance and strong Q3 beat across both revenue and EPS indicate accelerating momentum, particularly in the Life Sciences segment which returned to growth. The upcoming Investor Day on November 13 may provide further strategic detail on the post-divestiture business and long-term growth targets.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+5
Entry
$163.48
T+0 close · Nov 3, 2026 · via day close
Latest settled
−2.68%
T+5 · $159.10 · next T+20 in 15d
Vs SPY
−2.09%
α at T+5
Latest observation
−4.45%
T+8 · FF3 residual α
  1. T+0 · Nov 3 $163.48entry
  2. T+1 · 13d ago −2.48%α −4.13% · $159.43
  3. T+5 · 7d ago −2.68%α −2.09% · $159.10
  4. T+9 · todayOpen
  5. T+20 · in 15d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Revvity reported Q3 2026 adjusted EPS of $1.38, above the $1.30 consensus, on revenue of $729M versus the $694.7M consensus. The company raised its full-year 2026 guidance to pro forma adjusted EPS of $5.40-$5.45 and pro forma revenue of approximately $2.86 billion, citing broad-based growth and strong execution. The filing also included unaudited pro forma financial statements for the planned divestiture of its China Immunodiagnostics business, which is expected to close by the end of 2027.

Key Financial Metrics

EPS (Adj.)
$1.38
est $1.30 · +6.2% · GAAP: $0.56
Revenue
$728.9M
est $694.7M · +4.9% · +4.3% YoY
Rating
beat
Guidance
approximately $2.86 billion
raised
Free Cash Flow
$152.4M

Key Facts

  • Q3 2026 GAAP EPS from continuing operations was $0.56, compared to $0.41 in the prior year period.
  • Q3 2026 adjusted EPS from continuing operations was $1.38, compared to $1.18 in the prior year period.
  • Q3 2026 revenue was $729 million, compared to $699 million in the prior year period.
  • Pro forma revenue for Q3 2026 was $710 million, up 7% year-over-year.
  • Pro forma organic revenue growth was 7% for the quarter.
  • Life Sciences segment revenue was $380 million, up 11% pro forma; Diagnostics segment revenue was $349 million, up 4% pro forma.
  • Full-year 2026 guidance raised: pro forma revenue of approximately $2.86 billion, pro forma organic revenue growth of approximately 5%, and pro forma adjusted EPS of $5.40-$5.45.
  • The company entered into a definitive agreement to divest its China Immunodiagnostics business for up to $200 million, expected to close by end of 2027.
  • Investor Day scheduled for November 13, 2026.

Financial Impact

Q3 adjusted EPS of $1.38 beat consensus of $1.30 by 6.2%; revenue of $729M beat consensus of $694.7M by 4.9%. Full-year guidance raised to pro forma adjusted EPS of $5.40-$5.45 from prior $5.30-$5.40.

revenueepsguidance

Segment Breakdown

SegmentRevenueGrowth
Life Sciences$379.6M+10.7%
Diagnostics$349.3M-1.9%

Risk Factors

  • The China IDX divestiture is subject to regulatory approvals and may not close as anticipated.
  • Restructuring charges of $28.4 million in Q3 and $74.5 million year-to-date indicate ongoing cost actions that could signal underlying margin pressure.
  • Cash and cash equivalents declined to $593 million from $920 million at year-end 2025, partly due to debt repayment and share repurchases.

Market Snapshot

Exchange
NYSE
Sector
Laboratory Analytical Instruments
Analyst Consensus
44% bullish (25 analysts)

Investment Themes

Industrials & Manufacturing

Documents Analyzed

This report is based on 7 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0000031791-26-000031
Document: q32026proformafinancialsta.htm0000031791-26-000031
Document: pki-20261103.htm0000031791-26-000031
Document: 0000031791-26-000031-index-headers.html0000031791-26-000031
Document: 0000031791-26-000031-index.html0000031791-26-000031
Document: 0000031791-26-000031.txt0000031791-26-000031
8-K Data (Synthetic)0000031791-26-000031

Track record

9 reports on RVTY

Performance horizon

2 of 3 bullish or bearish reports moved the stock their way by T+20. Best: +45.31% at T+60 after the Aug 4, 2026 report. 3 of 3 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $150.78 Now $148.85 −1.28% settles Dec 15
  2. Nov 13, 20263d ago 8-K Neutral 4/10 Entry $154.39 Now $148.85 −3.59% settles Dec 14
  3. Nov 3, 202613d ago 8-K Bullish 6/10 Viewing Entry $163.48 Now $148.85 −8.95% settles Dec 2
  4. Oct 15, 20264w ago Institutional Cluster Neutral 3/10 Entry $154.64 to $158.25 Now $148.85 −3.74% ▲ +2.33% +3.75% vs SPY
  5. Oct 7, 20265w ago SC 13G/A Bullish 4/10 Entry $153.60 to $159.43 Now $148.85 −3.09% ▲ +3.80% +5.13% vs SPY
  6. Sep 23, 20267w ago Insider Cluster Bearish 4/10 Entry $150.61 to $157.29 Now $148.85 +1.17% ▼ −4.43% −4.85% vs SPY
  7. Aug 4, 202614w ago 8-K Bullish 7/10 Entry $111.39 to $126.59 Now $148.85 +33.63% ▲ +13.65% +14.88% vs SPY
  8. May 5, 202627w ago 8-K Mixed 5/10 Entry $92.30 to $100.39 Now $148.85 +61.27% ▲ +8.76% +3.81% vs SPY
  9. Mar 16, 202635w ago DEFA14A Neutral 3/10 Entry $86.41 to $93.44 Now $148.85 +72.26% ▲ +8.13% +4.35% vs SPY
Showing 9 of 9

US Market Status

Market Closed · Opens Wed (9h 44m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 3, 2026